Markets

Blood-based cancer diagnostics company Guardant Health files for a $100 million IPO

Guardant Health, which makes non-invasive blood-based cancer diagnostics tests, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.

The Redwood City, CA-based company was founded in 2013 and booked $67 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol GH. Guardant Health filed confidentially on July 5, 2018. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Blood-based cancer diagnostics company Guardant Health files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More